Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TranspoCART19 in Relapsed or Refractory B-cell Lymphoma
NCT06378190Phase 2Recruiting
- Sponsor
- Hospital Universitario de Salamanca
- Start
- Mar 2024
- Primary completion
- Jul 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of TranspoCART19 in B cell lymphoma, sponsored by Hospital Universitario de Salamanca. Started Mar 2024; status: recruiting.
02
Drugs
TranspoCART19
03
Conditions
B cell lymphoma
Beyond the preview
Go deeper on NCT06378190.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06378190.